ArticleBiochemistry and biophysics reports2025
Melatonin ameliorates astrogliosis and microgliosis in a cuprizone demyelinating mouse model.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Melatonin: A Silver Bullet for Fertility and Reproductive Health.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Synergistic effects of melatonin and curcumin in ameliorating experimental autoimmune encephalomyelitis: insights into anti-inflammatory, antioxidant, and neuroprotective mechanisms.Inflammopharmacology · 2025Article
- Molecular Links Between Circadian Rhythm Disruption, Melatonin, and Neurodegenerative Diseases: An Updated Review.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Several investigations have reported that melatonin is involved in the amelioration of the inflammatory process, improvement of myelin function, and regeneration in the central nervous system (CNS). The current study aimed to evaluate the protective effect of melatonin in cuprizone (CPZ)-induced myelin damage in the corpus callosum (CC) and explore the plausible underlying mechanisms of remyelination capacity and/or neuroprotection. Method: We administered cuprizone in chow either alone daily for 6 weeks or combined with simultaneously applied melatonin intra-peritoneal injections. we studied demyelination by LFB staining, oligodendrocyte staining using anti-Olig2 or anti-APC antibodies. In addition, we visualized microgliosis and astrocytosis by staining with anti-Iba-1 and anti-GFAP antibodies. Furthermore, we study the effect of melatonin on mRNA expression of Musashi-1, Hes-1 and Notch-1 genes. Results: Our data showed that cuprizone intoxication caused a significant oligodendrocyte loss, demyelination, and reactive gliosis in CC. Administration of melatonin prevented the demyelination in CC as determined by Luxol fast blue staining. Furthermore, we found that the melatonin significantly suppressed the cuprizone-induced microgliosis and astrocytosis. while the frequency of oligodendrocytes (Olig2+) was significantly enhanced in the CC after melatonin administration. In addition, melatonin significantly modulated Musashi1, Hes1, and Notch1 mRNA expression in the CC of mice. Conclusion: These results provide evidence that melatonin abolishes destructive cuprizone effects in the mouse corpus callosum by restoring oligodendrocyte generation, remyelination, and decreasing astrogliosis and microgliosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.